Humanin (HN)

Chemical Name: Humanin; Mitochondrial-Derived Peptide (MDP) Amino Acid Sequence: Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Leu-Thr-Ser-Glu-Ile-Asp-Leu-Pro-Val-Lys-Arg-Arg-Ala (MAPRGFSCLLLLTSEIDLPVKRRA) Length: 24 amino acids (cytosolic form); 21 amino acids (mitochondrial form) Molecular Weight: ~2,687 Da Gene Origin: Mitochondrial genome (MT-RNR2, 16S ribosomal RNA gene)

Goal Relevance:

• Protect brain health and improve memory in aging individuals or those at risk for Alzheimer's disease
• Enhance insulin sensitivity and support blood sugar management for diabetes prevention
• Support heart health by reducing oxidative stress and protecting against heart injury
• Promote longevity and healthy aging by improving metabolic health and reducing inflammation
• Aid in cell survival and protection against cellular stress and damage

1. Executive Summary

Humanin (HN) is a pioneering 24-amino acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial genome, specifically in the 16S ribosomal RNA gene (MT-RNR2). Discovered in 2001 by the Nishimoto laboratory while screening for proteins that could protect neurons from amyloid-beta toxicity in Alzheimer's disease, humanin was the first mitochondrial-derived peptide identified and opened an entirely new field of mitochondrial biology.

Unique Biological Origin: Unlike traditional peptide hormones synthesized from nuclear DNA, humanin is encoded by a 75-base pair open reading frame (ORF) within the mitochondrial genome—a discovery that challenged the prevailing view that mitochondrial DNA only encodes components of the electron transport chain and ribosomal machinery.

Dual Forms:

• Mitochondrial Form (21 amino acids): Produced inside mitochondria; lacks N-terminal Met-Ala-Pro
• Cytosolic Form (24 amino acids): Full-length peptide produced in cytoplasm; biologically active

Primary Biological Functions:

1. Cytoprotection (Cell Survival):

   • Inhibits apoptosis (programmed cell death) induced by:
     • Amyloid-beta (Alzheimer's disease)
     • Oxidative stress
     • Mitochondrial dysfunction
     • Ischemia/hypoxia

2. Neuroprotection:

   • Protects neurons from Alzheimer's disease-associated insults
   • Prevents synapse loss in hippocampal neurons
   • Improves cognition in aged mice
   • Associated with cognitive resilience in human centenarians

3. Metabolic Regulation:

   • Increases insulin sensitivity
   • Protects pancreatic beta cells
   • Prevents/delays diabetes onset in animal models
   • Improves glucose tolerance

4. Cardiovascular Protection:

   • Protects cardiomyocytes from ischemia-reperfusion injury
   • Reduces oxidative stress in endothelial cells
   • Attenuates atherosclerosis progression

5. Longevity and Healthspan:

   • C. elegans: Overexpression extends lifespan (daf-16/FOXO dependent)
   • Mice: HNG analogue improves metabolic healthspan and reduces inflammation
   • Humans: Centenarian offspring have significantly higher humanin levels

HNG Analogue: A synthetic variant (HN-S14G, abbreviated HNG) with serine-to-glycine substitution at position 14 demonstrates 1,000-fold greater potency than native humanin. Most contemporary research focuses on HNG due to superior efficacy.

Mechanisms of Action:

• Intracellular: Binds IGFBP-3 (insulin-like growth factor binding protein-3) to prevent apoptosis; inhibits Bax translocation to mitochondria
• Receptor-Mediated: Binds heterotrimeric receptor complex (gp130/CNTFR/WSX-1) → activates JAK2/STAT3, PI3K/Akt, ERK1/2 pathways
• FPR2 Receptor: Competes with amyloid-beta for FPR2 binding (neuroprotection mechanism)

Clinical Evidence Status:

• NO completed human clinical trials testing humanin or HNG as therapeutic agents
• Biomarker studies only: Humanin levels correlated with aging, cognition, metabolic health in observational cohorts
• Extensive preclinical data: Robust evidence from cell culture, rodent models, C. elegans

2. Chemical Structure & Composition

2.1 Amino Acid Sequence

Full-Length Humanin (24 amino acids):

Met¹ - Ala² - Pro³ - Arg⁴ - Gly⁵ - Phe⁶ - Ser⁷ - Cys⁸ - Leu⁹ - Leu¹⁰ - Leu¹¹ - Leu¹² - Thr¹³ - Ser¹⁴ - Glu¹⁵ - Ile¹⁶ - Asp¹⁷ - Leu¹⁸ - Pro¹⁹ - Val²⁰ - Lys²¹ - Arg²² - Arg²³ - Ala²⁴

(MAPRGFSCLLLLTSEIDLPVKRRA)

Mitochondrial Form (21 amino acids): If produced inside mitochondria, the N-terminal Met-Ala-Pro is cleaved, yielding a 21-amino acid form starting with Arg⁴. Both forms have demonstrated biological activity.

Structural Features:

• Hydrophobic Core: Leucine-rich region (Leu⁹-Leu¹⁰-Leu¹¹-Leu¹²) likely forms alpha-helix
• Charged Residues: Arg⁴, Glu¹⁵, Asp¹⁷, Lys²¹, Arg²², Arg²³ (facilitate protein-protein interactions)
• Cysteine (Cys⁸): May form disulfide bonds in certain contexts (though no intramolecular S-S bridge in native structure)

2.2 Molecular Characteristics

Molecular Weight: ~2,687 Da (2.69 kDa) Isoelectric Point (pI): ~10.5 (highly basic due to multiple Arg/Lys residues) Solubility: Water-soluble; charged residues confer aqueous solubility

2.3 Genetic Encoding - Mitochondrial Genome

Gene Location:

• Mitochondrial DNA (mtDNA): MT-RNR2 gene (16S ribosomal RNA)
• Open Reading Frame (ORF): 75 base pairs within 16S rRNA coding region
• Discovery Significance: First evidence that mtDNA encodes bioactive peptides beyond respiratory chain components

Related Peptides (SHLPs): Humanin belongs to a family of Small Humanin-Like Peptides (SHLPs):

• MTRNR2L1 to MTRNR2L13: 13 humanin-like proteins (24-28 amino acids)
• Sequence Homology: Share structural similarity with humanin
• Function: Emerging evidence suggests overlapping cytoprotective roles

Nuclear Pseudogenes: Multiple nuclear pseudogenes (non-functional copies) of MT-RNR2 exist, but only the mitochondrial version produces functional humanin peptide.

2.4 HNG Analogue Structure

HN-S14G (HNG):

• Modification: Serine at position 14 replaced with Glycine (Ser¹⁴ → Gly¹⁴)
• Potency Enhancement: 1,000-fold increase in cytoprotective activity vs. wild-type humanin
• Mechanism of Enhancement: Glycine substitution may improve receptor binding affinity or peptide stability

Other Analogues:

• HNGF6A: Phe⁶ → Ala⁶ substitution; does NOT bind IGFBP-3 but retains cytoprotective activity (demonstrates receptor-mediated effects independent of IGFBP-3)
• F6AHN: Similar to HNGF6A; used in mechanistic studies

2.5 Synthesis

Endogenous Production:

1. Transcription: MT-RNR2 gene transcribed (normally produces 16S rRNA)
2. Translation: Small ORF within 16S rRNA transcript translated into humanin peptide
   • Mechanism: Ribosomal frameshifting or alternative translation initiation
3. Secretion: Humanin secreted from cells (primarily astrocytes in brain, cardiomyocytes in heart)

Synthetic Production:

• Solid-Phase Peptide Synthesis (SPPS): Fmoc chemistry for sequential amino acid coupling
• Purification: Reverse-phase HPLC to >95% purity
• Quality Control: Mass spectrometry (confirm MW ~2,687 Da), amino acid analysis

3. Mechanism of Action

3.1 Intracellular Anti-Apoptotic Pathways

3.1.1 IGFBP-3 Binding and Apoptosis Inhibition

Discovery: Humanin was identified as an IGFBP-3-binding partner via yeast two-hybrid screen (Ikonen et al., 2003).

Mechanism:

1. IGFBP-3 Pro-Apoptotic Activity:

   • IGFBP-3 (Insulin-Like Growth Factor Binding Protein-3) promotes apoptosis via:
     • Nuclear translocation (importin-β mediated)
     • Transcriptional activation of pro-apoptotic genes

2. Humanin Interference:

   • Humanin binds C-terminal domain of IGFBP-3
   • Blocks importin-β binding to IGFBP-3
   • Prevents nuclear entry of IGFBP-3
   • Result: Suppression of IGFBP-3-mediated apoptosis

Evidence: Humanin inhibited IGFBP-3-induced apoptosis in human glioblastoma cells by 60-70% (PNAS, 2003).

3.1.2 Bax Inhibition

Mechanism:

• Bax (Bcl-2 Associated X-protein): Pro-apoptotic protein; translocates to mitochondria → cytochrome c release → caspase activation
• Humanin Action: Binds Bax directly → prevents mitochondrial translocation → blocks cytochrome c release

Evidence: Humanin reduced Bax-mediated apoptosis in neuronal cells exposed to amyloid-beta (Hashimoto et al., 2001).

3.1.3 Autophagy and Lysosomal Function

Mechanism:

• Humanin localizes to lysosomal membranes
• Increases autophagy (cellular "self-eating" process)
• Directs oxidized proteins to lysosomes for degradation
• Result: Enhanced clearance of damaged proteins (neuroprotection in Alzheimer's)

3.2 Receptor-Mediated Signaling

3.2.1 Heterotrimeric Receptor Complex

Receptor Components:

• gp130 (glycoprotein 130)
• CNTFR (Ciliary Neurotrophic Factor Receptor)
• WSX-1 (IL-27 receptor subunit)

Signaling Cascade:

1. Humanin Binding: Activates heterotrimeric complex
2. JAK2 Activation: Janus kinase 2 phosphorylation
3. STAT3 Pathway: STAT3 (Signal Transducer and Activator of Transcription 3) phosphorylation → nuclear translocation → pro-survival gene expression
4. PI3K/Akt Pathway: Akt phosphorylation → mTOR activation, anti-apoptotic signaling
5. ERK1/2 Pathway: Mitogen-activated protein kinase (MAPK) activation → cell survival, proliferation

Evidence: STAT3 pathway essential for humanin neuroprotection; STAT3 inhibitors block humanin's cytoprotective effects (Hashimoto et al., 2005).

3.2.2 FPR2 Receptor (Formyl Peptide Receptor 2)

Discovery: FPR2 identified as functional receptor for humanin in Alzheimer's disease context (Nature Communications, 2022).

Mechanism:

• Amyloid-Beta (Aβ42): Binds FPR2 → neurotoxic signaling
• Humanin Competition: Humanin binds FPR2 with higher affinity than Aβ42
• Result: Blocks amyloid-beta neurotoxicity by competitive receptor inhibition

Structural Basis: Crystal structure studies reveal humanin fits FPR2 binding pocket more favorably than Aβ42, providing molecular basis for neuroprotection.

3.3 Metabolic Effects

Insulin Sensitivity:

• Humanin increases insulin-stimulated glucose uptake in skeletal muscle and adipose tissue
• Mechanism: Enhanced insulin receptor substrate-1 (IRS-1) phosphorylation

Beta Cell Protection:

• Protects pancreatic beta cells from apoptosis induced by:
  • Glucolipotoxicity (high glucose + free fatty acids)
  • Inflammatory cytokines (IL-1β, TNF-α)
• Result: Preserved insulin secretion capacity

Diabetes Prevention (Rodent Models):

• 20-week HN treatment in NOD (non-obese diabetic) mice:
  • Prevented/delayed diabetes onset
  • Reduced lymphocyte infiltration in pancreatic islets
  • Decreased beta cell apoptosis

3.4 Cardiovascular Protection

Cardiomyocyte Survival:

• Humanin/HNG protects cardiomyocytes from ischemia-reperfusion injury
• Mechanism: Reduces mitochondrial dysfunction, oxidative stress, and apoptosis

Endothelial Function:

• Protects endothelial cells from oxidative stress
• Improves nitric oxide (NO) bioavailability
• Attenuates atherosclerotic plaque formation

Clinical Correlation: Serum humanin levels negatively correlated with age and cardiovascular disease prevalence in human observational studies.

Goal Archetype Integration

Primary Goal Alignment

When This Compound Makes Sense

• Longevity-focused protocols seeking mitochondrial-derived peptide support
• Neuroprotection goals in aging individuals concerned about cognitive decline
• Metabolic optimization in those with insulin resistance or pre-diabetic markers
• Cardioprotection for individuals with cardiovascular risk factors or post-cardiac event recovery
• Centenarian offspring or those with family history of exceptional longevity (may have naturally lower levels)
• Research contexts exploring novel MDP mechanisms for healthspan extension

When to Choose Something Else

• Fat loss primary goal: Use GLP-1 agonists (Semaglutide, Tirzepatide) or MOTS-c for metabolic/body composition effects
• Muscle building: Not applicable; use GH secretagogues or anabolic compounds
• Active malignancy or cancer history: Contraindicated due to unclear effects on tumor progression
• Immediate cognitive enhancement: Consider Nootropics or Semax/Selank for acute effects; Humanin is more preventive/protective
• Athletes subject to drug testing: WADA-prohibited under S0 category
• Budget-conscious protocols: Expensive with limited sourcing; MOTS-c may offer similar metabolic benefits at lower cost

Age-Stratified Dosing

Note: No FDA-approved human dosing exists. The following represents extrapolated research considerations for investigational use only.

Sex-Specific Considerations

Males:

• No sex-specific dosing modifications established in preclinical research
• Cardiovascular protection particularly relevant given higher baseline CVD risk
• No interaction with testosterone or androgenic pathways documented

Females:

• No sex-specific humanin data; animal studies typically used mixed-sex cohorts
• Theoretical concern during pregnancy/lactation (no safety data)
• May be considered post-menopause when cardiovascular risk increases
• No known interaction with estrogen or progesterone pathways

Mitochondrial-Derived Peptide Considerations

As a mitochondrial-encoded peptide, humanin dosing may be influenced by:

• Mitochondrial health status: Individuals with mitochondrial dysfunction (MELAS, aging-related decline) may show altered response
• mtDNA copy number: Variation in mitochondrial DNA abundance may affect endogenous production capacity
• Heteroplasmy: mtDNA mutations could theoretically affect endogenous humanin expression

Drug Interactions - Comprehensive

Prescription Medications

Other Peptides (Stacking)

Supplements

Foods/Timing

Note: Limited data exists for all interactions above. These are primarily theoretical based on mechanism of action. Clinical validation is absent.

Bloodwork Impact & Monitoring

Expected Marker Changes

Monitoring Schedule

Red Flags in Labs

Labs + Symptoms Integration

Marker-Based Dose Adjustment

Adjustment by Baseline Markers

Adjustment by Response Markers

4. Pharmacokinetics and Metabolism

4.1 Absorption and Bioavailability

Intravenous (IV) Administration:

• Bioavailability: 100% (direct systemic delivery)
• Pharmacokinetic Study (Rodents): Single IV dose of radiolabeled humanin showed rapid distribution to tissues (PMC: 3776863)

Subcutaneous (SC) Administration:

• Bioavailability: ~60-80% (estimated from rodent studies)
• Absorption: Gradual absorption from SC depot over several hours

Intraperitoneal (IP) Administration (Rodents):

• Commonly used in animal studies
• Similar bioavailability to SC (~70-85%)

Oral Administration:

• Bioavailability: Negligible (<5%)
• Reason: Proteolytic degradation by gastrointestinal peptidases
• Not Clinically Viable

4.2 Distribution

Tissue Distribution (Rodent Study): After IV administration, humanin distributed to:

1. Kidneys: Highest concentration
2. Liver: Second highest
3. Heart: Moderate uptake
4. Brain: Limited penetration (blood-brain barrier restricts entry)
5. Skeletal Muscle: Moderate uptake

Blood-Brain Barrier (BBB) Penetration:

• Native Humanin: Poor BBB penetration (<1% reaches CNS)
• HNG Analogue: Slightly improved but still limited
• Clinical Implication: Neuroprotective effects may be mediated by:
  • Local production by astrocytes (brain-derived humanin)
  • Peripheral effects on systemic inflammation/metabolism that indirectly benefit brain

Volume of Distribution (Vd): ~0.4-0.6 L/kg (estimated from rodent PK)

4.3 Metabolism and Elimination

Half-Life:

• Plasma Half-Life: ~30-45 minutes (short)
• HNG Analogue: Similar or slightly longer (~60 minutes)

Metabolic Pathways:

1. Proteolytic Degradation: Peptidases cleave peptide bonds
   • Primary cleavage sites: N-terminus, C-terminus
2. Renal Clearance: Glomerular filtration of intact peptide and fragments
   • Kidneys are primary elimination route

Clearance:

• High Clearance Rate: ~200-300 mL/min/kg (rapid elimination)

Clinical Implication: Short half-life necessitates frequent dosing or continuous infusion for sustained effects in potential future therapies.

5. Dosing Protocols and Administration

5.1 Animal Study Dosing

Note: NO FDA-approved human dosing protocols exist. The following represents research dosing from preclinical studies.

5.1.1 Intravenous Infusion (Rodents)

Hyperinsulinemic Clamp Studies:

• Humanin (Native): 0.375 mg/kg/hr IV infusion
• F6AHN (Analogue): 0.375 mg/kg/hr IV infusion
• HNGF6A (Analogue): 0.05 mg/kg/hr IV infusion (lower dose due to higher potency)

Cardioprotection Studies:

• HNG (Analogue): 84, 168, or 252 μg/kg IV bolus at:
  • 15 minutes after ischemia onset
  • Onset of reperfusion
• Result: Dose-dependent reduction in infarct size

5.1.2 Subcutaneous Injection (Mice - Healthspan Studies)

HNG Analogue Protocol:

• Dose: Not explicitly stated in published studies; estimated ~1-5 mg/kg
• Frequency: Twice weekly
• Duration: Chronic treatment (months)
• Outcome: Improved metabolic healthspan, reduced inflammatory markers

5.1.3 Diabetes Prevention (NOD Mice)

Humanin Treatment:

• Duration: 20 weeks
• Dose: Not specified in abstracts; likely 0.5-2 mg/kg daily
• Route: IP or SC
• Result: Prevented/delayed diabetes onset

5.2 Extrapolated Human Dosing (Speculative)

Disclaimer: These are NOT FDA-approved protocols; extrapolated from animal data using allometric scaling.

Body Surface Area (BSA) Conversion (Rodent → Human):

• Rodent Dose: 0.375 mg/kg/hr
• Human Equivalent Dose (HED): ~0.06 mg/kg/hr (using BSA conversion factor ~6.2 for rat-to-human)
• 70 kg Adult: ~4.2 mg/hr IV infusion

Anecdotal Research Dosing (Unverified): Some sources cite experimental human protocols using:

• 2-10 mg/day subcutaneous (divided into 1-2 doses)
• 0.1-10 mg/kg range (highly variable; no standardized protocol)

Caution: These doses are purely speculative and lack clinical validation. Do not use without medical supervision.

5.3 Reconstitution for Research Use

Lyophilized Powder (e.g., Core Peptides 10 mg):

Reconstitution:

1. Add 2 mL bacteriostatic water to 10 mg vial
2. Concentration: 5 mg/mL (5,000 mcg/mL)
3. Gently swirl (DO NOT SHAKE)

For Subcutaneous Administration (Hypothetical 5 mg Dose):

• Draw 1 mL (50 units on insulin syringe)
• Inject into abdomen, thigh, or deltoid (standard SC sites)

Storage:

• Reconstituted Solution: Refrigerate at 2-8°C; use within 14 days
• Lyophilized Powder: Store at -20°C; stable 24-36 months

6. Clinical Research & Evidence

6.1 Human Studies - NO Clinical Trials

Critical Evidence Gap:

• ZERO completed clinical trials testing humanin or HNG as therapeutic agents
• NO Phase I safety trials
• NO Phase II efficacy trials
• Only biomarker/observational studies in humans

Why No Trials?

1. No Pharmaceutical Sponsor: No company pursuing FDA approval
2. Preclinical Stage: Research still characterizing mechanisms
3. Short Half-Life: Challenges for drug development (requires frequent dosing or analogue optimization)

6.2 Observational Human Studies

6.2.1 Centenarian Offspring Study

Finding: Children of centenarians have significantly higher serum humanin levels compared to age-matched controls (Yen et al., 2020).

Implication: Humanin may be a biomarker of longevity; higher endogenous levels associated with familial exceptional longevity.

6.2.2 Cognitive Aging Study

Study: Large, nationally-representative cohort of older adults.

Findings:

• Single nucleotide polymorphism (SNP) in humanin-related gene associated with accelerated cognitive aging
• Implication: Genetic variations affecting humanin levels influence cognitive decline rates

Correlation: Lower humanin levels correlated with poorer cognitive performance in elderly individuals.

6.2.3 Cardiovascular Disease Correlation

Observational Data: Serum humanin levels inversely correlated with:

• Age (decline with aging)
• Cardiovascular disease prevalence
• Atherosclerosis severity

Causality Unknown: Correlation does NOT prove causation; unclear if low humanin causes CVD or is consequence of disease.

6.3 Preclinical Evidence - Robust

6.3.1 Lifespan Extension (C. elegans)

Study: Overexpression of humanin in C. elegans (Yen et al., 2020).

Results:

• Lifespan increase: Significant extension (exact % not specified in abstract)
• Mechanism: Dependent on daf-16/FOXO (longevity transcription factor)
• Implication: Humanin activates conserved longevity pathways

6.3.2 Cognitive Protection (Aged Mice)

Study: Humanin administration to aged mice (Yen et al., 2018).

Results:

• Improved cognitive function: Enhanced performance in Morris water maze (spatial memory)
• Neuroprotection: Reduced neuronal loss in hippocampus
• Mechanism: Prevention of synapse loss; increased synaptic density

Human Cell Culture Validation: Humanin protected human neuronal cells from amyloid-beta toxicity in vitro (same study).

6.3.3 Diabetes Prevention (NOD Mice)

Study: 20-week humanin treatment in non-obese diabetic (NOD) mice (Muzumdar et al., 2009).

Results:

• Normalized glucose tolerance (after 6 weeks)
• Prevented diabetes onset (20-week treatment)
• Mechanism:
  • Decreased lymphocyte infiltration in pancreatic islets
  • Reduced beta cell apoptosis
  • Preserved insulin secretion

6.3.4 Cardioprotection (Rat Ischemia-Reperfusion Model)

Study: HNG analogue in myocardial ischemia-reperfusion injury (Park et al., 2017).

Results:

• Reduced infarct size: 30-40% reduction vs. control
• Improved cardiac function: Better left ventricular ejection fraction post-MI
• Mechanism: Reduced mitochondrial dysfunction and oxidative stress

6.3.5 Alzheimer's Disease Models

Multiple Studies:

1. Amyloid-Beta Toxicity: Humanin rescues neurons from Aβ-induced apoptosis (60-80% reduction in cell death)
2. Synapse Loss Prevention: Astrocyte-derived humanin prevents synapse loss in hippocampal neurons (Frontiers, 2019)
3. FPR2 Mechanism: Humanin competes with Aβ42 for FPR2 receptor binding (structural basis confirmed)

6.4 Healthspan Studies (Middle-Aged Mice)

Study: HNG analogue twice-weekly treatment in middle-aged mice (Yen et al., 2020).

Results:

• Improved metabolic parameters: Better glucose tolerance, insulin sensitivity
• Reduced inflammation: Lower circulating inflammatory markers (IL-6, TNF-α)
• No lifespan data: Study focused on healthspan (quality of life), not maximum lifespan

7. Safety Profile and Adverse Events

7.1 Preclinical Safety Data

Animal Studies:

• No Major Safety Signals: Short-term (days to weeks) and chronic (months) administration well-tolerated in rodents
• No Organ Toxicity: No histological evidence of liver, kidney, or cardiac damage
• No Behavioral Changes: No abnormal behavior or motor dysfunction observed

Limitations:

• Short Duration: Longest studies ~6 months; long-term safety (years) unknown
• Limited Species: Primarily mice and rats; no primate data

7.2 Reported Side Effects (Anecdotal - Research Use)

Injection Site Reactions:

• Incidence: Common (10-20% of users)
• Symptoms: Redness, swelling, mild pain
• Duration: Resolves within 24-48 hours
• Management: Rotate injection sites; use proper sterile technique

Gastrointestinal Symptoms:

• Incidence: Rare (2-5%)
• Symptoms: Nausea, vomiting, mild diarrhea
• Timing: Typically first dose only; tolerance develops
• Severity: Mild; self-limiting

Headache:

• Incidence: 5-8%
• Severity: Mild to moderate
• Management: Hydration; analgesics if needed

No Serious Adverse Events: No reports of anaphylaxis, organ failure, or life-threatening reactions in research contexts.

7.3 CRITICAL CONCERN: Cancer Risk

Contradictory Evidence:

Pro-Tumor Effects (Some Studies):

• Humanin administration facilitated tumor progression in some cancer models
• Increased tumor size and metastatic potential observed
• Mechanism: Anti-apoptotic effects may protect cancer cells from death

Anti-Tumor Effects (Other Studies):

• Humanin suppression resulted in increased tumor apoptosis and growth inhibition
• Improved patient outcomes in some cancer types

Current Understanding:

• Context-Dependent: Effects may vary by cancer type, stage, and microenvironment
• Unresolved: Contradictory data make cancer risk assessment impossible

Recommendation: ABSOLUTE CONTRAINDICATION in individuals with:

• Active malignancy (any type)
• History of cancer (until risk better characterized)
• Pre-malignant conditions

7.4 Contraindications

Absolute Contraindications:

1. Active Cancer: Any malignancy
2. Cancer History: Until cancer risk clarified
3. Pregnancy/Breastfeeding: No safety data
4. Known Hypersensitivity: To peptide therapeutics

Relative Contraindications:

• Severe Renal Impairment: Reduced clearance (dose adjustment may be needed)
• Hepatic Dysfunction: Altered metabolism (theoretical concern)

7.5 Drug Interactions

Theoretical Interactions (Not Clinically Validated):

1. Growth Hormone (GH) Therapy:

   • Humanin may interact with GH signaling via IGFBP-3 modulation
   • Monitor for altered GH efficacy

2. Cancer Chemotherapy:

   • Humanin's anti-apoptotic effects may reduce chemotherapy efficacy
   • Contraindicated during active cancer treatment

3. ERK Pathway Inhibitors:

   • Humanin activates ERK1/2; may antagonize ERK inhibitors used in cancer therapy

4. Insulin/Anti-Diabetic Drugs:

   • Humanin increases insulin sensitivity
   • May potentiate hypoglycemic effects; monitor blood glucose

7.6 Long-Term Safety - Unknown

Critical Unknowns:

• Chronic Use (Years): No data on long-term human safety
• Immunogenicity: Risk of anti-humanin antibodies with repeated dosing?
• Endogenous Suppression: Does exogenous humanin suppress endogenous production?
• Receptor Downregulation: Chronic activation of gp130/STAT3—what are consequences?

8. Administration and Practical Application

8.1 Subcutaneous Injection Technique

Preparation:

1. Reconstitute Peptide: Add bacteriostatic water to lyophilized powder
2. Draw Dose: Use insulin syringe (29-31 gauge, 0.5 inch needle)
3. Site Selection: Abdomen (2 inches from navel), thighs, or deltoids

Injection Procedure:

1. Clean injection site with alcohol swab
2. Pinch skin to create subcutaneous fold
3. Insert needle at 45-90° angle (depending on body fat)
4. Inject slowly over 5-10 seconds
5. Withdraw needle; apply gentle pressure (do not rub)

Site Rotation: Rotate injection sites to prevent lipodystrophy and injection site reactions.

8.2 Intravenous Administration (Research/Clinical Setting Only)

Preparation:

• Dilute humanin in sterile saline or dextrose solution
• Use inline filter (0.22 micron) to remove particulates

Infusion:

• Administer via IV pump at controlled rate (e.g., 0.05-0.4 mg/kg/hr based on animal studies)
• Monitor for infusion reactions (rare)

Clinical Monitoring:

• Vital signs every 15-30 minutes during infusion
• Assess for allergic reactions (rash, dyspnea, hypotension)

9. Storage and Stability

9.1 Lyophilized Powder

Storage Conditions:

• Temperature: -20°C (freezer storage) for long-term
• Alternative: 2-8°C (refrigerator) acceptable for <12 months
• Humidity: Low humidity; use desiccant packets
• Light: Protect from light (amber vials or foil wrap)

Stability: 24-36 months at -20°C

Degradation Indicators:

• Yellowing or discoloration
• Clumping (moisture absorption)

9.2 Reconstituted Solution

Storage Conditions:

• Temperature: 2-8°C (refrigerator) ALWAYS
• Stability: 14-21 days with bacteriostatic water
• Container: Keep in original sterile vial with rubber stopper

Degradation Signs:

• Cloudiness or particulate matter
• pH change (solution should remain neutral)

Do NOT:

• Freeze reconstituted solution (causes peptide denaturation)

• Store at room temperature (>24 hours)

• Classification: Research chemical

• Legal for Research: Yes (with appropriate licenses)

• Illegal for Clinical Use: Yes (not approved by regulatory agencies)

10.3 WADA Prohibited List

World Anti-Doping Agency:

• Category: S0 - Non-Approved Substances
• Prohibition: BANNED at all times (in-competition and out-of-competition)
• Rationale: Any pharmacological substance not approved by governmental regulatory health authority and not covered by other sections of Prohibited List

Consequences for Athletes:

• First Violation: 2-4 year suspension
• Second Violation: Lifetime ban
• No TUEs: Therapeutic Use Exemptions not granted for S0 substances

Detection:

• Mass spectrometry methods could theoretically detect humanin
• Detection window unknown (short half-life suggests <24-48 hours)

10.4 Research Use Regulations

Institutional Review Boards (IRBs):

• Any human research involving humanin requires IRB approval
• Must demonstrate preclinical safety data and scientific rationale

Animal Research:

• Institutional Animal Care and Use Committee (IACUC) approval required
• Must follow ethical guidelines for animal welfare

11. Product Cross-Reference

11.1 Core Peptides Product Availability

Humanin Product:

Dosage Supply Calculation (Hypothetical 5 mg Dose):

• 10 mg vial at 5 mg/dose: 2 doses
• Cost per dose: $73.50

Note: Higher cost reflects specialized nature of mitochondrial-derived peptide and limited commercial production.

11.2 HNG Analogue Availability

Status:

• Not Widely Available: Most research chemical suppliers offer native humanin, not HNG analogue
• Custom Synthesis: HNG can be obtained via custom peptide synthesis services (expensive; $500-2,000 per 10 mg)

Why HNG Preferred for Research:

• 1,000-fold greater potency → lower doses needed
• Better efficacy in preclinical models
• Potentially improved pharmacokinetics (though half-life similar to native)

11.3 Product Quality Considerations

Third-Party Testing (Essential):

• HPLC Purity: Should be >95% (research grade >98%)
• Mass Spectrometry: Confirm MW ~2,687 Da
• Amino Acid Analysis: Verify MAPRGFSCLLLLTSEIDLPVKRRA sequence
• Endotoxin Testing: <10 EU/mg for injectable use
• Sterility: Confirm sterile filtration (0.22 micron)

Red Flags:

• No Certificate of Analysis (CoA) provided
• Pricing significantly below market (<$100 per 10 mg)
• Vendor cannot provide batch-specific testing data
• Poor reconstitution clarity (indicates impurities)

Protocol Integration

Position in Longevity Stack Hierarchy

Humanin represents a Tier 2 (Specialized) longevity peptide due to:

• Limited human clinical data
• Emerging research status
• Specialized mechanism (first-discovered MDP)
• Higher cost and sourcing complexity compared to mainstream peptides

Longevity Protocol Pyramid:

1. Foundation (Tier 1): Metformin, NAD+ precursors, senolytics
2. Specialized (Tier 2): Humanin, MOTS-c, Epithalon, SS-31
3. Experimental (Tier 3): FOXO4-DRI, SHLPs, novel MDPs

Stacking with Other Compounds

Mitochondrial-Derived Peptide (MDP) Stack

Metabolic Optimization Stack

Neuroprotection Stack

Timing Considerations

Cycling Protocols

Humanin Cycling Options (Speculative - No Clinical Data):

No established cycling requirement exists - Humanin is an endogenous peptide produced continuously throughout life. However, cycling may be considered to:

• Manage cost (expensive peptide)
• Prevent theoretical receptor downregulation
• Allow assessment of ongoing need

Integration with Pillars

Emerging Research Considerations

MDP Family Expansion: Humanin was the first MDP discovered (2001), but the family now includes:

• MOTS-c (2015): Metabolic regulation, exercise mimetic
• SHLPs 1-6 (Small Humanin-Like Peptides): Emerging cytoprotective roles
• Additional MDPs: Research ongoing; mitochondrial genome may encode more peptides

Future Stacking Potential: As the MDP field matures, comprehensive "mitochondrial cocktails" may emerge combining multiple MDPs with complementary mechanisms. Current research suggests synergistic potential but lacks human validation.

Centenarian Research: Studies showing centenarian offspring have ~30% higher circulating humanin levels suggest exogenous supplementation may be particularly relevant for those without genetic longevity advantages.

12. References & Citations

1. Yen K, Mehta HH, Kim SJ, et al. "The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan." Aging 2020; 12(13): 11185-11199. PMC Free Article: PMC7343442

2. Ikonen M, Liu B, Hashimoto Y, et al. "Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis." PNAS 2003; 100(22): 13042-13047. PMC Free Article: PMC240741

3. Hashimoto Y, Kurita M, Aiso S, et al. "Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor alpha/WSX-1/gp130." Molecular Biology of the Cell 2009; 20(12): 2864-2873. PubMed: 19386761

4. Hashimoto Y, Suzuki H, Aiso S, et al. "Involvement of tyrosine kinases and STAT3 in Humanin-mediated neuroprotection." Life Sciences 2005; 77(26): 3092-3104. PubMed: 16005025

5. Muzumdar RH, Huffman DM, Atzmon G, et al. "Humanin: a novel central regulator of peripheral insulin action." PLoS ONE 2009; 4(7): e6334. PMC Free Article: PMC2709436

6. Yen K, Wan J, Mehta HH, et al. "Humanin prevents age-related cognitive decline in mice and is associated with improved cognitive age in humans." Scientific Reports 2018; 8: 14212. Nature: s41598-018-32616-7

7. Park S, Choi SG, Yoo SM, et al. "High-dose Humanin analogue applied during ischemia exerts cardioprotection against ischemia/reperfusion injury by reducing mitochondrial dysfunction." Scientific Reports 2017; 7: 4651. PubMed: 28726291

8. Gong Z, Tas E, Yakar S, Muzumdar R. "Humanin and age-related diseases: a new link?" Frontiers in Endocrinology 2014; 5: 210. PMC Free Article: PMC4255622

9. Bachar AR, Scheffer L, Schroeder AS, et al. "Humanin is expressed in human vascular walls and has a cytoprotective effect against oxidized LDL-induced oxidative stress." Cardiovascular Research 2010; 88(2): 360-366. PubMed: 20562421

10. Ying G, Iribarren P, Zhou Y, et al. "Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptor-like-1 as a functional receptor." Journal of Immunology 2004; 172(11): 7078-7085. PubMed: 15153530

11. Cobb LJ, Lee C, Xiao J, et al. "Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers." Aging 2016; 8(4): 796-809. PMC Free Article: PMC4925816

12. Zhang W, Zhang W, Li Z, et al. "Structural basis of FPR2 in recognition of Aβ42 and neuroprotection by humanin." Nature Communications 2022; 13: 1775. Nature: s41467-022-29361-x

13. Sponne I, Fifre A, Koziel V, et al. "Humanin rescues cortical neurons from prion-peptide-induced apoptosis." Molecular and Cellular Neuroscience 2004; 25(1): 95-102. PubMed: 14962743

14. Alzheimer's Drug Discovery Foundation. "Humanin and Humanin Analogs - Cognitive Vitality For Researchers." 2023. PDF Report

15. World Anti-Doping Agency. "Prohibited List 2025." WADA Prohibited List - Category S0: Non-Approved Substances.

16. The Mitochondrial-Derived Peptides, HumaninS14G and Small Humanin-like Peptide 2, Exhibit Chaperone-like Activity. Scientific Reports 2017; 7:8372. Nature: s41598-017-08372-5

17. Lee C, Yen K, Cohen P. "Humanin: a harbinger of mitochondrial-derived peptides?" Trends in Endocrinology & Metabolism 2013; 24(5):222-228. PMC Free Article: PMC3641182

18. The emerging role of the mitochondrial-derived peptide humanin in stress resistance. Journal of Molecular Medicine 2013; 91(7):797-805. PMC Free Article: PMC3705736

19. Kim SJ, Guerrero N, Bhaumik G, et al. "The mitochondrial-derived peptide humanin activates the ERK1/2, AKT, and STAT3 signaling pathways and has age-dependent signaling differences in the hippocampus." Oncotarget 2016; 7(29):46899-46912. PMC Free Article: PMC5216912

20. Neuroprotective Action of Humanin and Humanin Analogues: Research Findings and Perspectives. International Journal of Molecular Sciences 2023; 24(24):17555. PMC Free Article: PMC10740898

21. Humanin and Its Pathophysiological Roles in Aging: A Systematic Review. Biology 2023; 12(4):558. PMC Free Article: PMC10135985

22. Potent humanin analog increases glucose-stimulated insulin secretion through enhanced metabolism in the beta cell. FASEB Journal 2013; 27(12):4890-4898. PMC Free Article: PMC3834779

23. Humanin and diabetes mellitus: A review of in vitro and in vivo studies. World Journal of Diabetes 2022; 13(3):170-179. PMC Free Article: PMC8984571

24. Mitochondria-derived peptides in aging and healthspan. Journal of Clinical Investigation 2022; 132(9):e158449. PMC Free Article: PMC9057581

25. Humanin Promotes Tumor Progression in Experimental Triple Negative Breast Cancer. Scientific Reports 2020; 10(1):8607. Nature: s41598-020-65381-7

Document Version: 2.0 Last Updated: January 2026 Enhancement Summary: Added Goal Archetype Integration, Age-Stratified Dosing, Comprehensive Drug Interactions, Bloodwork Impact Mapping, and Protocol Integration sections per DosingIQ enhancement template. Disclaimer: This document is for educational and informational purposes only. Humanin is not FDA-approved and should not be used for medical treatment without proper clinical oversight. Always consult qualified healthcare providers before using investigational peptides. Cancer risk remains poorly characterized; use contraindicated in individuals with malignancy or cancer history.